Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay J Mathew

Showing results (51-60 of 190) with videos related to

Pageof 19
Sort By:
Journal of Clinical Psychopharmacology|April 8, 2025
Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical TrialSanjay J Mathew, Andrew J Cutler, Nicole C Visitacion, et al.
Annals of the New York Academy of Sciences|February 5, 2015
The promise of ketamine for treatment-resistant depression: current evidence and future directionsKaitlin E DeWilde, Cara F Levitch, James W Murrough, et al.
Journal of Affective Disorders|August 29, 2018
Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depressionSamuel T Wilkinson, Carly Kiselycznyk, Mounira Banasr, et al.
Advances in Neurobiology|March 17, 2023
Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel TherapeuticsRudy Lozano Carreon, Ana Maria Rivas-Grajales, Nicholas Murphy, et al.
Journal of Psychopharmacology (Oxford, England)|August 15, 2014
Hippocampal volume and the rapid antidepressant effect of ketamineChadi G Abdallah, Ramiro Salas, Andrea Jackowski, et al.
Translational Psychiatry|July 4, 2026
High-order brain interactions during ketamine-induced state changes: A functional marker of response in late-life treatment-resistant depression?Krisha Shah, Rubén Herzog, Alan C Swann, et al.
CNS Drugs|February 7, 2012
Ketamine for treatment-resistant unipolar depression: current evidenceSanjay J Mathew, Asim Shah, Kyle Lapidus, et al.
CNS Drugs|July 28, 2010
Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonistsJohn H Krystal, Sanjay J Mathew, D Cyril D'Souza, et al.
The International Journal of Neuropsychopharmacology|November 29, 2020
Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant DepressionAna Maria Rivas-Grajales, Ramiro Salas, Meghan E Robinson, et al.
Bipolar Disorders|February 15, 2012
Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trialAmit Anand, Abigail D Gunn, Gavriel Barkay, et al.
Pageof 19

Showing results (51-60 of 190) with videos related to

Sort By:
Pageof 19
Journal of Clinical Psychopharmacology|April 8, 2025
Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical TrialSanjay J Mathew, Andrew J Cutler, Nicole C Visitacion, et al.
Annals of the New York Academy of Sciences|February 5, 2015
The promise of ketamine for treatment-resistant depression: current evidence and future directionsKaitlin E DeWilde, Cara F Levitch, James W Murrough, et al.
Journal of Affective Disorders|August 29, 2018
Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depressionSamuel T Wilkinson, Carly Kiselycznyk, Mounira Banasr, et al.
Advances in Neurobiology|March 17, 2023
Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel TherapeuticsRudy Lozano Carreon, Ana Maria Rivas-Grajales, Nicholas Murphy, et al.
Journal of Psychopharmacology (Oxford, England)|August 15, 2014
Hippocampal volume and the rapid antidepressant effect of ketamineChadi G Abdallah, Ramiro Salas, Andrea Jackowski, et al.
Translational Psychiatry|July 4, 2026
High-order brain interactions during ketamine-induced state changes: A functional marker of response in late-life treatment-resistant depression?Krisha Shah, Rubén Herzog, Alan C Swann, et al.
CNS Drugs|February 7, 2012
Ketamine for treatment-resistant unipolar depression: current evidenceSanjay J Mathew, Asim Shah, Kyle Lapidus, et al.
CNS Drugs|July 28, 2010
Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonistsJohn H Krystal, Sanjay J Mathew, D Cyril D'Souza, et al.
The International Journal of Neuropsychopharmacology|November 29, 2020
Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant DepressionAna Maria Rivas-Grajales, Ramiro Salas, Meghan E Robinson, et al.
Bipolar Disorders|February 15, 2012
Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trialAmit Anand, Abigail D Gunn, Gavriel Barkay, et al.
Pageof 19